Please assess the completion status of the following clinical trial:

Trial Title: Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* History of breast cancer, ductal carcinoma in situ, or lobular carcinoma in situ (currently without evidence of malignant disease) OR~* Concerns about taking estrogen for fear of breast cancer~* Bothersome hot flashes, defined as occurrence at least 14 times per week and of sufficient severity as to make patient desire therapeutic intervention~* Presence of hot flashes for at least 1 month~* Hormone receptor status:~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Sex:~* Female~Performance status:~* ECOG 0-1~Life expectancy:~* At least 6 months~Cardiovascular:~* No prior thromboembolic disease~* No uncontrolled hypertension (persistent diastolic blood pressure greater than 95 mm Hg and/or systolic blood pressure greater than 160 mm Hg)~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Chemotherapy:~* More than 4 weeks since prior antineoplastic chemotherapy~* No concurrent antineoplastic chemotherapy unless clinically appropriate~Endocrine therapy:~* More than 4 weeks since prior androgen or estrogen therapy~* More than 3 months since prior progesterone as part of hormone replacement therapy~* At least 1 year since any other progesterone therapy (including megestrol)~* No concurrent androgen, estrogen, or progestational agents unless clinically appropriate~* Concurrent tamoxifen, raloxifene, or aromatase inhibitors are allowed if started more than 4 weeks ago and continuation for more than 5 weeks is planned~Other:~* More than 2 weeks since prior agents for treatment of hot flashes (e.g., clonidine, Bellergal-S, or vitamin E of more than 400 mg per day)~* More than 1 year since prior antidepressants (including Hypericum perforatum \[St John's Wort\])~* No other concurrent antidepressants or monoamine oxidase inhibitors~* No other concurrent agents for treatment of hot flashes (e.g. clonidine, Bellergal-S, or vitamin E of more than 400 mg per day)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I: venlafaxine (Type: EXPERIMENTAL): All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive oral venlafaxine once daily for 6 weeks beginning on day 8. After week 7, patients with satisfactory efficacy may continue venlafaxine for up to 6 months. Patients with unsatisfactory efficacy may cross over to arm III.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12.
- Arm II: medroxyprogesterone - long term (Type: EXPERIMENTAL): All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone intramuscularly (IM) on days 8, 22, and 36 for a total of 3 injections. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12.
- Arm III: medroxyprogesterone - short term (Type: EXPERIMENTAL): All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone IM once on day 8. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).